| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.
|
Cancer Cell
|
2007
|
7.24
|
|
2
|
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma.
|
Blood
|
2005
|
5.82
|
|
3
|
Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study.
|
Blood
|
2009
|
5.69
|
|
4
|
Clonal competition with alternating dominance in multiple myeloma.
|
Blood
|
2012
|
4.39
|
|
5
|
New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes.
|
J Clin Oncol
|
2012
|
3.35
|
|
6
|
Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma.
|
Mayo Clin Proc
|
2006
|
2.88
|
|
7
|
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013.
|
Mayo Clin Proc
|
2013
|
2.59
|
|
8
|
Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement.
|
Mayo Clin Proc
|
2007
|
2.55
|
|
9
|
Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma.
|
J Clin Oncol
|
2009
|
2.50
|
|
10
|
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease.
|
Blood
|
2011
|
2.45
|
|
11
|
Stem cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide induction.
|
Blood
|
2010
|
2.40
|
|
12
|
Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma.
|
Mayo Clin Proc
|
2007
|
2.34
|
|
13
|
Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling.
|
Cancer Res
|
2007
|
2.19
|
|
14
|
Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients.
|
Blood
|
2009
|
2.12
|
|
15
|
Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3.
|
Blood
|
2011
|
2.07
|
|
16
|
Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application.
|
Br J Haematol
|
2005
|
1.99
|
|
17
|
Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component.
|
Mayo Clin Proc
|
2009
|
1.96
|
|
18
|
Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma.
|
Biol Blood Marrow Transplant
|
2013
|
1.88
|
|
19
|
Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2.
|
Blood
|
2009
|
1.86
|
|
20
|
Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone.
|
Blood
|
2009
|
1.86
|
|
21
|
Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma.
|
Blood
|
2004
|
1.82
|
|
22
|
Salvage second hematopoietic cell transplantation in myeloma.
|
Biol Blood Marrow Transplant
|
2013
|
1.80
|
|
23
|
Idiopathic systemic capillary leak syndrome (Clarkson's disease): the Mayo clinic experience.
|
Mayo Clin Proc
|
2010
|
1.80
|
|
24
|
Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma.
|
Blood
|
2005
|
1.79
|
|
25
|
Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells.
|
Cancer Res
|
2006
|
1.72
|
|
26
|
Early reduction of serum-free light chains associates with renal recovery in myeloma kidney.
|
J Am Soc Nephrol
|
2011
|
1.57
|
|
27
|
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation.
|
Biol Blood Marrow Transplant
|
2010
|
1.56
|
|
28
|
Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis.
|
Leuk Lymphoma
|
2008
|
1.54
|
|
29
|
Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation.
|
Nephrol Dial Transplant
|
2011
|
1.51
|
|
30
|
The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma.
|
Proc Natl Acad Sci U S A
|
2006
|
1.46
|
|
31
|
VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis.
|
Blood
|
2004
|
1.46
|
|
32
|
The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome.
|
Blood
|
2011
|
1.46
|
|
33
|
Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie.
|
Mayo Clin Proc
|
2010
|
1.34
|
|
34
|
Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma): a single-center experience.
|
Blood
|
2012
|
1.32
|
|
35
|
Cardiac amyloidosis: a practical approach to diagnosis and management.
|
Am J Med
|
2011
|
1.31
|
|
36
|
Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model.
|
Clin Cancer Res
|
2007
|
1.30
|
|
37
|
Transplantation for amyloidosis.
|
Curr Opin Oncol
|
2007
|
1.29
|
|
38
|
FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance.
|
Cancer Res
|
2005
|
1.25
|
|
39
|
Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis.
|
Blood
|
2005
|
1.23
|
|
40
|
Plasma cell labeling index.
|
Methods Mol Med
|
2005
|
1.22
|
|
41
|
Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications.
|
Blood
|
2010
|
1.13
|
|
42
|
Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative.
|
Mayo Clin Proc
|
2008
|
1.13
|
|
43
|
Clinical implication of centrosome amplification in plasma cell neoplasm.
|
Blood
|
2005
|
1.11
|
|
44
|
Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma.
|
Am J Hematol
|
2010
|
1.10
|
|
45
|
Use of nonclonal serum immunoglobulin free light chains to predict overall survival in the general population.
|
Mayo Clin Proc
|
2012
|
1.09
|
|
46
|
Tumor-associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myeloma.
|
Am J Hematol
|
2009
|
1.08
|
|
47
|
The importance of bone marrow examination in determining complete response to therapy in patients with multiple myeloma.
|
Blood
|
2009
|
1.07
|
|
48
|
An oncolytic measles virus engineered to enter cells through the CD20 antigen.
|
Mol Ther
|
2003
|
1.07
|
|
49
|
Progression in smoldering Waldenstrom macroglobulinemia: long-term results.
|
Blood
|
2012
|
1.06
|
|
50
|
Autologous stem cell transplant after heart transplant for light chain (Al) amyloid cardiomyopathy.
|
J Heart Lung Transplant
|
2008
|
1.03
|
|
51
|
Proteasome beta subunit pharmacogenomics: gene resequencing and functional genomics.
|
Clin Cancer Res
|
2008
|
1.02
|
|
52
|
Cytokine and chemokine profiles in multiple myeloma; significance of stromal interaction and correlation of IL-8 production with disease progression.
|
Leuk Res
|
2006
|
1.02
|
|
53
|
Review: extramedullary disease in multiple myeloma.
|
Clin Adv Hematol Oncol
|
2009
|
1.01
|
|
54
|
Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway.
|
Oncogene
|
2005
|
0.97
|
|
55
|
Differential cytopathology and kinetics of measles oncolysis in two primary B-cell malignancies provides mechanistic insights.
|
Mol Ther
|
2011
|
0.96
|
|
56
|
Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization.
|
Biol Blood Marrow Transplant
|
2012
|
0.95
|
|
57
|
Differential expression of vascular endothelial growth factors and their receptors in multiple myeloma.
|
Haematologica
|
2006
|
0.95
|
|
58
|
Efficacy of bortezomib as first-line treatment for patients with multiple myeloma.
|
Clin Med Insights Oncol
|
2013
|
0.95
|
|
59
|
Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo.
|
Blood
|
2005
|
0.95
|
|
60
|
TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells.
|
Am J Hematol
|
2010
|
0.95
|
|
61
|
SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma.
|
Blood
|
2005
|
0.95
|
|
62
|
Clinical features of patients with immunoglobulin light chain amyloidosis (AL) with vascular-limited deposition in the kidney.
|
Nephrol Dial Transplant
|
2011
|
0.94
|
|
63
|
Renal failure due to combined cast nephropathy, amyloidosis and light-chain deposition disease.
|
Nephrol Dial Transplant
|
2010
|
0.94
|
|
64
|
Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis.
|
Haematologica
|
2009
|
0.93
|
|
65
|
Anti-myeloma activity of Akt inhibition is linked to the activation status of PI3K/Akt and MEK/ERK pathway.
|
PLoS One
|
2012
|
0.93
|
|
66
|
Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma.
|
Blood
|
2011
|
0.93
|
|
67
|
Treatment for high-risk smoldering myeloma.
|
N Engl J Med
|
2013
|
0.92
|
|
68
|
Idiotype-pulsed antigen-presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival.
|
Am J Hematol
|
2009
|
0.92
|
|
69
|
Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors.
|
Oncogene
|
2005
|
0.91
|
|
70
|
Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma.
|
Br J Haematol
|
2009
|
0.91
|
|
71
|
Outcome of patients with IgD and IgM multiple myeloma undergoing autologous hematopoietic stem cell transplantation: a retrospective CIBMTR study.
|
Clin Lymphoma Myeloma Leuk
|
2010
|
0.90
|
|
72
|
Incidence of monoclonal gammopathy of undetermined significance and estimation of duration before first clinical recognition.
|
Mayo Clin Proc
|
2012
|
0.90
|
|
73
|
Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma.
|
Blood
|
2011
|
0.90
|
|
74
|
High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.
|
N Engl J Med
|
2008
|
0.90
|
|
75
|
Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin.
|
Am J Hematol
|
2011
|
0.90
|
|
76
|
Therapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agents.
|
Leuk Lymphoma
|
2014
|
0.90
|
|
77
|
R-(-)-gossypol (AT-101) activates programmed cell death in multiple myeloma cells.
|
Exp Hematol
|
2008
|
0.90
|
|
78
|
The significance of monoclonal gammopathy of undetermined significance.
|
Haematologica
|
2009
|
0.88
|
|
79
|
Solitary plasmacytoma: is radiation therapy sufficient?
|
Am J Hematol
|
2008
|
0.88
|
|
80
|
Serum immunoglobulin free light chain measurements and heavy chain isotype usage provide insight into disease biology in patients with POEMS syndrome.
|
Am J Hematol
|
2010
|
0.87
|
|
81
|
Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myeloma.
|
Eur J Haematol
|
2010
|
0.86
|
|
82
|
Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma.
|
Br J Haematol
|
2003
|
0.85
|
|
83
|
Urinary albumin excretion patterns of patients with cast nephropathy and other monoclonal gammopathy-related kidney diseases.
|
Clin J Am Soc Nephrol
|
2012
|
0.85
|
|
84
|
A detailed evaluation of the current renal response criteria in AL amyloidosis: is it time for a revision?
|
Haematologica
|
2013
|
0.85
|
|
85
|
Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma.
|
Am J Hematol
|
2010
|
0.85
|
|
86
|
Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies.
|
Leuk Lymphoma
|
2014
|
0.84
|
|
87
|
Systemic amyloidosis associated with chronic lymphocytic leukemia/small lymphocytic lymphoma.
|
Am J Hematol
|
2013
|
0.83
|
|
88
|
The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma.
|
Future Oncol
|
2015
|
0.83
|
|
89
|
Impact of high-risk classification by FISH: an eastern cooperative oncology group (ECOG) study E4A03.
|
Br J Haematol
|
2011
|
0.83
|
|
90
|
Hematopoietic recovery kinetics predicts for poor CD34+ cell mobilization after cyclophosphamide chemotherapy in multiple myeloma.
|
Am J Hematol
|
2011
|
0.83
|
|
91
|
Successful treatment of scleromyxedema with autologous peripheral blood stem cell transplantation.
|
Arch Dermatol
|
2005
|
0.83
|
|
92
|
Akt inhibitor MK2206 selectively targets CLL B-cell receptor induced cytokines, mobilizes lymphocytes and synergizes with bendamustine to induce CLL apoptosis.
|
Br J Haematol
|
2013
|
0.82
|
|
93
|
Acute renal failure secondary to severe type I cryoglobulinemia following rituximab therapy for Waldenström's macroglobulinemia.
|
Clin Exp Nephrol
|
2008
|
0.81
|
|
94
|
Low levels of interleukin-1 receptor antagonist (IL-1RA) predict engraftment syndrome after autologous stem cell transplantation in POEMS syndrome and other plasma cell neoplasms.
|
Biol Blood Marrow Transplant
|
2013
|
0.80
|
|
95
|
Cell Trafficking in Multiple Myeloma.
|
Open J Hematol
|
2012
|
0.79
|
|
96
|
Treatment trade-offs in myeloma: A survey of consecutive patients about contemporary maintenance strategies.
|
Cancer
|
2013
|
0.79
|
|
97
|
Current advances in non-proteasome inhibitor-based approaches to the treatment of relapsed/refractory multiple myeloma.
|
Oncology (Williston Park)
|
2011
|
0.78
|
|
98
|
Evaluation of pretransplant factors predicting cardiac dysfunction following high-dose melphalan conditioning and autologous peripheral blood stem cell transplantation.
|
Eur J Haematol
|
2012
|
0.78
|
|
99
|
Immunoglobulin m monoclonal gammopathy of undetermined significance and smoldering Waldenström macroglobulinemia.
|
Clin Lymphoma Myeloma Leuk
|
2013
|
0.78
|
|
100
|
Mobilization and transplantation patterns of autologous hematopoietic stem cells in multiple myeloma and non-Hodgkin lymphoma.
|
Cancer Control
|
2015
|
0.77
|
|
101
|
On appetite and its loss.
|
J Clin Oncol
|
2003
|
0.77
|
|
102
|
Acute kidney injury during leukocyte engraftment after autologous stem cell transplantation in patients with light-chain amyloidosis.
|
Am J Hematol
|
2011
|
0.77
|
|
103
|
IgM monoclonal gammopathy of undetermined significance (MGUS) and smoldering Waldenström's macroglobulinemia (SWM).
|
Clin Lymphoma Myeloma Leuk
|
2011
|
0.77
|
|
104
|
Initial treatment of transplant-eligible patients in multiple myeloma.
|
Expert Rev Hematol
|
2014
|
0.76
|
|
105
|
Factors associated with favorable outcome after allogeneic hematopoietic stem cell transplantation for multiple myeloma.
|
Leuk Lymphoma
|
2009
|
0.75
|
|
106
|
Reply to S. Girnius et al.
|
J Clin Oncol
|
2013
|
0.75
|
|
107
|
Conflicts of interest, authorship, and disclosures in industry-related scientific publications.
|
Mayo Clin Proc
|
2010
|
0.75
|
|
108
|
Differences in the distribution of cytogenetic subtypes between multiple myeloma patients with and without a family history of monoclonal gammopathy and multiple myeloma.
|
Eur J Haematol
|
2013
|
0.75
|
|
109
|
Candidate genes of Waldenström's macroglobulinemia: current evidence and research.
|
Appl Clin Genet
|
2013
|
0.75
|
|
110
|
Residual serum monoclonal protein predicts progression-free survival in patients with previously untreated multiple myeloma.
|
Cancer
|
2010
|
0.75
|
|
111
|
A novel report of cig-FISH and cytogenetics in POEMS syndrome.
|
Am J Hematol
|
2008
|
0.75
|
|
112
|
Impact of dexamethasone responsiveness on long term outcome in patients with newly diagnosed multiple myeloma.
|
Br J Haematol
|
2009
|
0.75
|
|
113
|
Genetic variants in DNA repair pathways are not associated with disease progression among multiple myeloma patients.
|
Leuk Res
|
2013
|
0.75
|
|
114
|
Activity of bortezomib administered once every 3 weeks for treatment of relapsed multiple myeloma.
|
Leuk Lymphoma
|
2009
|
0.75
|
|
115
|
Corrigendum: Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients.
|
Nat Commun
|
2015
|
0.75
|
|
116
|
An unusual neurological complication of light chain amyloidosis.
|
Br J Haematol
|
2009
|
0.75
|